menu
    • menu

    Company profile for Blueprint Medicines

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. We believe our ability to identify novel drivers of disease, coupled with our proprietary library of nov...
    Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. We believe our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Blueprint MedicinesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Blueprint Medicines 45 Sidney Street Cambridge, MA 02139
    Telephone
    Telephone
    617-374-7580
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.blueprintmedicines.com:443/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/blueprint-medicines
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BlueprintMeds?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's Blueprint Medicines Showcases Ayvakit Benefits At ASH
    Sanofi's Blueprint Medicines Showcases Ayvakit Benefits At ASH

    05 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-a-sanofi-company-highlights-long-term-clinical-benefit-of-ayvakit-avapritinib-across-indolent-and-advanced-systemic-mastocytosis-at-2025-ash-annual-meeting-302633712.html

    PR NEWSWIRE
    05 Dec 2025
    Share Share
    Sanofi Completes Acquisition of Blueprint Medicines
    Sanofi Completes Acquisition of Blueprint Medicines

    19 Jul 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-18-05-00-00-3117709

    PRESS RELEASE
    19 Jul 2025
    Share Share
    Sanofi Extends Blueprint Tender Offer Period
    Sanofi Extends Blueprint Tender Offer Period

    17 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/17/3116948/0/en/Press-Release-Sanofi-announces-extension-of-Blueprint-tender-offer.html

    GLOBENEWSWIRE
    17 Jul 2025
    Share Share
    Cogent Hits Primary Endpoint, Building Case for Blueprint Rival
    Cogent Hits Primary Endpoint, Building Case for Blueprint Rival

    07 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cogents-phase-3-hits-primary-endpoint-building-case-filing-challenge-blueprints-ayvakit

    FIERCE BIOTECH
    07 Jul 2025
    Share Share
    Blueprint Medicines: Data on AYVAKIT® Treatment at 2025 Congresse
    Blueprint Medicines: Data on AYVAKIT® Treatment at 2025 Congresse

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-reinforcing-sustained-clinical-efficacy-and-well-tolerated-safety-profile-of-long-term-ayvakitayvakyt-avapritinib-treatment-at-2025-eha-and-eaaci-congresses-302480690.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    Sanofi to buy US biopharma group Blueprint for over $9 billion
    Sanofi to buy US biopharma group Blueprint for over $9 billion

    03 Jun 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541

    PRESS RELEASE
    03 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search